Ultrathin-strut drug-eluting stents are associated with lower revascularization rates than drug-coated balloons in non-focal in-stent restenosis
Frontiers in Cardiovascular Medicine · 03.08.2026 · 13
DOI: 10.3389/fcvm.2026.1865693 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Cardiovascular Medicine, online erschienen am 03.08.2026. Verfasst von Berhan Keskin und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Istanbul Medipol University, Medipol Mega University Hospital, Istanbul, Türkiye. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
In-stent restenosis (ISR) remains a significant clinical challenge despite advances in drug-eluting stent (DES) technology. Although current guidelines recommend drug-coated balloon (DCB) angioplasty or repeat DES implantation for DES-ISR, real-world data comparing DCB with newer-generation ultrathin-strut sirolimus-eluting stents (SES) are limited.
Methods
This retrospective, single-center study included consecutive patients with stable angina who underwent treatment for DES-ISR using either a paclitaxel-coated DCB or an ultrathin-strut SES between January 2015 and May 2025. The primary outcome was target-lesion revascularization (TLR). Secondary endpoints included major adverse cardiac events (MACE), defined as a composite of all-cause mortality, myocardial infarction, stroke, and TLR. Time-to-event analyses were performed using Kaplan–Meier methods and Cox proportional hazards regression.
Results
A total of 205 patients were included (DCB, n = 106; SES, n = 99), with a median follow-up of 863 days. In the overall cohort, TLR rates were comparable between groups. However, in the non-focal ISR subgroup, TLR was significantly higher in the DCB group compared with SES (34.1% vs. 12.7%, p = 0.024). Similarly, MACE rates were higher with DCB in non-focal ISR (39.0% vs. 18.2%, p = 0.041). No differences were observed in focal ISR. Multivariable analysis in the non-focal subgroup identified DCB treatment (HR 3.89, p = 0.006) as independent predictor of TLR. Kaplan–Meier analyses for TLR and MACE consistently demonstrated significantly worse outcomes with DCB in the non-focal ISR subgroup, whereas no significant differences were observed in focal ISR.
Conclusions
Ultrathin-strut SES was associated with lower TLR and MACE rates compared with DCB in non-focal DES-ISR, whereas outcomes were comparable in focal ISR. These findings highlight the importance of lesion characteristics and support a tailored approach to ISR management.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiology, Istanbul Medipol University, Medipol Mega University Hospital, Istanbul, Türkiye.
Zitieren
APA
Keskin, B., Hakgor, A., Dursun, A., Akhundova, A., Savur, U., Yigitbay, E., Onder, O., Cakal, B., Bayram, Z., Demir, B., Gunes, H. M., Karaca, I. O., Guler, E., & Boztosun, B. (2026). Ultrathin-strut drug-eluting stents are associated with lower revascularization rates than drug-coated balloons in non-focal in-stent restenosis. Frontiers in Cardiovascular Medicine, 13. https://doi.org/10.3389/fcvm.2026.1865693
Vancouver
Keskin B, Hakgor A, Dursun A, Akhundova A, Savur U, Yigitbay E, et al. Ultrathin-strut drug-eluting stents are associated with lower revascularization rates than drug-coated balloons in non-focal in-stent restenosis. Frontiers in Cardiovascular Medicine. 2026;13. doi:10.3389/fcvm.2026.1865693
BibTeX
@article{Keskin2026,
author = {Keskin, Berhan and Hakgor, Aykun and Dursun, Atakan and Akhundova, Aysel and Savur, Umeyir and Yigitbay, Ebubekir and Onder, Ozlem and Cakal, Beytullah and Bayram, Zubeyde and Demir, Bulent and Gunes, Haci Murat and Karaca, Ibrahim Oguz and Guler, Ekrem and Boztosun, Bilal},
title = {Ultrathin-strut drug-eluting stents are associated with lower revascularization rates than drug-coated balloons in non-focal in-stent restenosis},
journal = {Frontiers in Cardiovascular Medicine},
year = {2026},
volume = {13},
doi = {10.3389/fcvm.2026.1865693}
}
EUVIMED